<- Go Home

Virbac SA

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is a vaccine for porcine circovirus type 2; and Suigen Donoban is a multivalent vaccine used for the prevention of respiratory diseases in swine. It also provides a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, immunology, nutrition, petfood, and pharmaceutical products. In addition, the company serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.

Market Cap

EUR 2.8B

Volume

4.5K

Cash and Equivalents

EUR 122.5M

EBITDA

EUR 277.0M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

EUR 976.7M

Profit Margin

66.68%

52 Week High

EUR 389.50

52 Week Low

EUR 296.00

Dividend

0.43%

Price / Book Value

2.51

Price / Earnings

18.72

Price / Tangible Book Value

5.25

Enterprise Value

EUR 3.0B

Enterprise Value / EBITDA

10.29

Operating Income

EUR 230.1M

Return on Equity

13.88%

Return on Assets

7.65

Cash and Short Term Investments

EUR 126.2M

Debt

EUR 289.6M

Equity

EUR 1.1B

Revenue

EUR 1.5B

Unlevered FCF

EUR 131.0M

Sector

Pharmaceuticals

Category

N/A

Company Stock Pitches